These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 15720781)

  • 21. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
    Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV
    Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.
    Savcic M; Hauert J; Bachmann F; Wyld PJ; Geudelin B; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():15-9. PubMed ID: 10440417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
    Saint-Martin F; Dumur JP; Pérez I; Izquierdo I;
    J Investig Allergol Clin Immunol; 2004; 14(1):34-40. PubMed ID: 15160440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs.
    Furuya A; Nozawa M; Gotoh J; Jingu S; Akimoto M; Higuchi S; Suwa T; Ogata H
    J Pharm Pharmacol; 2002 Jul; 54(7):921-7. PubMed ID: 12162710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies.
    Gaussem P; Reny JL; Thalamas C; Chatelain N; Kroumova M; Jude B; Boneu B; Fiessinger JN
    J Thromb Haemost; 2005 Jul; 3(7):1437-45. PubMed ID: 15978101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
    Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers.
    Adamus WS; Heuer H; Meade CJ
    Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):415-20. PubMed ID: 2747341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
    Russell T; Stoltz M; Weir S
    Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
    Matsushima N; Jakubowski JA; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):218-26. PubMed ID: 16769599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of plasma concentrations of SCH 44643 by a GC method and correlation of plasma concentration and anti-PAF activity in cynomolgus monkeys.
    Lin CC; Billah M; Kim HK; Egan R; Anthes J; Gilchrest H; Cayen M
    J Pharm Biomed Anal; 1996 Dec; 15(3):343-7. PubMed ID: 8951694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A technique for population pharmacodynamic analysis of concentration-binary response data.
    Bailey JM; Gregg KM
    Anesthesiology; 1997 Apr; 86(4):825-35. PubMed ID: 9105227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triazolam and PAF.
    Lancet; 1991 Dec; 338(8780):1459-60. PubMed ID: 1683442
    [No Abstract]   [Full Text] [Related]  

  • 35. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models.
    Gueorguieva I; Ogungbenro K; Graham G; Glatt S; Aarons L
    Comput Methods Programs Biomed; 2007 Apr; 86(1):51-61. PubMed ID: 17292995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacodynamic Modeling Using the Sigmoid E
    Proost JH; Eleveld DJ; Struys MMRF
    AAPS J; 2020 Dec; 23(1):10. PubMed ID: 33367961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simulation for the analysis of distorted pharmacodynamic data.
    Hashimoto Y; Ozaki J; Koue T; Odani A; Yasuhara M; Hori R
    Pharm Res; 1994 Apr; 11(4):545-8. PubMed ID: 8058613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic principles and the time course of immediate drug effects.
    Holford N
    Transl Clin Pharmacol; 2017 Dec; 25(4):157-161. PubMed ID: 32095468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol.
    Morentin Gutierrez P; Yates J; Nilsson C; Birtles S
    Pharmacol Res Perspect; 2019 Apr; 7(2):e00465. PubMed ID: 30899516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.
    Leary PJ; Rajasekaran S; Morrison RR; Tuomanen EI; Chin TK; Hofmann PA
    Am J Physiol Heart Circ Physiol; 2008 Jun; 294(6):H2775-84. PubMed ID: 18441203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.